These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 20347862)

  • 21. Endocannabinoids, metabolic regulation, and the role of diet.
    Carr TP; Jesch ED; Brown AW
    Nutr Res; 2008 Oct; 28(10):641-50. PubMed ID: 19083471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The endocannabinoid system: its roles in energy balance and potential as a target for obesity treatment.
    André A; Gonthier MP
    Int J Biochem Cell Biol; 2010 Nov; 42(11):1788-801. PubMed ID: 20541029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cannabinoid receptors: where they are and what they do.
    Mackie K
    J Neuroendocrinol; 2008 May; 20 Suppl 1():10-4. PubMed ID: 18426493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
    Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
    Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The endocannabinoid system and gut-brain signalling.
    Storr MA; Sharkey KA
    Curr Opin Pharmacol; 2007 Dec; 7(6):575-82. PubMed ID: 17904903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dysregulation of the endocannabinoid system in obesity.
    Engeli S
    J Neuroendocrinol; 2008 May; 20 Suppl 1():110-5. PubMed ID: 18426509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endocannabinoids and food consumption: comparisons with benzodiazepine and opioid palatability-dependent appetite.
    Cooper SJ
    Eur J Pharmacol; 2004 Oct; 500(1-3):37-49. PubMed ID: 15464019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Latest advances in cannabinoid receptor agonists.
    Thakur GA; Tichkule R; Bajaj S; Makriyannis A
    Expert Opin Ther Pat; 2009 Dec; 19(12):1647-73. PubMed ID: 19939187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review.
    Svízenská I; Dubový P; Sulcová A
    Pharmacol Biochem Behav; 2008 Oct; 90(4):501-11. PubMed ID: 18584858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cannabinoid signalling regulates inflammation and energy balance: the importance of the brain-gut axis.
    Cluny NL; Reimer RA; Sharkey KA
    Brain Behav Immun; 2012 Jul; 26(5):691-8. PubMed ID: 22269477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.
    Hadcock JR; Griffith DA; Iredale PA; Carpino PA; Dow RL; Black SC; O'Connor R; Gautreau D; Lizano JS; Ward K; Hargrove DM; Kelly-Sullivan D; Scott DO
    Biochem Biophys Res Commun; 2010 Apr; 394(2):366-71. PubMed ID: 20211605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Importance of the endocannabinoid system in the regulation of energy homeostasis].
    Kvasnicka T
    Vnitr Lek; 2008 Feb; 54(2):191-4. PubMed ID: 23687711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minireview: Endocannabinoids and their receptors as targets for obesity therapy.
    de Kloet AD; Woods SC
    Endocrinology; 2009 Jun; 150(6):2531-6. PubMed ID: 19372200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cannabinoid receptors and their ligands.
    Pertwee RG; Ross RA
    Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):101-21. PubMed ID: 12052030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas.
    Li C; Jones PM; Persaud SJ
    Pharmacol Ther; 2011 Mar; 129(3):307-20. PubMed ID: 21055418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of the endocannabinoid system in the control of energy homeostasis.
    Osei-Hyiaman D; Harvey-White J; Bátkai S; Kunos G
    Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S33-8. PubMed ID: 16570103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
    Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Fong TM; Shen CP; Lao J; Xiao JC; Shearman LP; Stribling DS; Rosko K; Strack A; Marsh DJ; Feng Y; Kumar S; Samuel K; Yin W; Van der Ploeg LH; Goulet MT; Hagmann WK
    J Med Chem; 2006 Dec; 49(26):7584-7. PubMed ID: 17181138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. From endocannabinoid profiling to 'endocannabinoid therapeutics'.
    Ligresti A; Petrosino S; Di Marzo V
    Curr Opin Chem Biol; 2009 Jun; 13(3):321-31. PubMed ID: 19497779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocannabinoid synthesis and degradation, and their regulation in the framework of energy balance.
    Matias I; Di Marzo V
    J Endocrinol Invest; 2006; 29(3 Suppl):15-26. PubMed ID: 16751706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
    Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR
    J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.